The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,959.00
Bid: 1,952.00
Ask: 1,954.00
Change: 20.00 (1.03%)
Spread: 2.00 (0.102%)
Open: 1,940.00
High: 1,971.00
Low: 1,940.00
Prev. Close: 1,939.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Admiral Rises After Strong Half-Year Results

Wed, 15th Aug 2018 10:40

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------Admiral Group, up 5.0%. The motor and home insurer reported an increased interim profit driven by a good performance its UK Motor division, prompting a 7% dividend hike. Admiral posted a 9.1% increase in pretax profit to GBP211.0 million from GBP193.4 million a year before. Revenue increased 14% to GBP1.66 billion from GBP1.45 billion. Return on equity fell to 54% from 55% in the same period last year. Admiral saw an 11% profit increase in its UK Motor division, to GBP249.5 million from GBP224.2 million, in the period, mainly as a result of "growth in ancillary revenue and installment income". The company is proposing an interim dividend of 60.0 pence per share, a 7.1% increase year-on-year from 56.0p paid a year previously.----------GlaxoSmithKline, up 1.5%. The drugmaker said its majority-owned HIV specialist company ViiV Healthcare saw positive headline results from its phase III antiretroviral therapy as long-acting suppression study for the treatment of human immunodeficiency virus. Glaxo said the study showed long-acting cabotegravir and rilpivirine, injected once a month, had similar efficacy to a standard of care, daily, oral three-drug regimen at Week 48. The injectable treatment regimen met the primary endpoint for non-inferiority, Glaxo said. Overall safety, virologic response and drug resistance results for the injectable regimen were consistent with results from the phase II LATTE and LATTE-2 studies.----------FTSE 100 - LOSERS----------Fresnillo, down 2.9% and Randgold Resources, down 2.5%. The gold miners were tracking spot gold prices lower quoted at USD1,186.69 an ounce compared to USD1,196.85 at the London equities close Tuesday as the precious metal traded around its worst levels since January 2017.----------BHP Billiton, down 2.0%, Glencore, down 1.9%, Antofagasta, down 1.8%, Anglo American, down 1.7%, Rio Tinto, down 1.6%. The miners were lower amid a strengthening dollar and lower copper prices. "The price of copper has this week hit a 13-month low following a sharp slowdown in China's fixed-asset investment growth. This news, together with waning investor appetite for riskier assets, has unsurprisingly put a dent in the mining sector," said AJ Bell's Russ Mould. Midcap peer Kaz Minerals was down 3.6%.----------FTSE 250 - WINNERS----------Hikma Pharmaceuticals, up 8.5%. The drugmaker raised its annual revenue target for its Injectables and Generics divisions following a significant uplift in profit in the first half of 2018. Hikma said pretax profit for the six months to the end of June totalled USD141.0 million, up from USD100.0 million reported for the same period a year earlier, as revenue climbed 11% to USD989.0 million from USD895.0 million. On a constant currency basis, revenue rose by 10%. Hikma raised its full-year guidance for the Injectables unit and now expects revenue for 2018 to come in between USD775 million and USD825 million. Previously, Hikma targeted the Injectables division to achieve revenue growth in a range of USD750 million to USD800 million. The company declared an interim dividend of 12 cents per share, up from 11 cents paid the year before. ----------Balfour Beatty, up 3.6%. The infrastructure company reported a drop in interim revenue but increased profit, boosting its interim payout as a result. Balfour said pretax profit rose to GBP50 million from just GBP12 million the year before. Revenue decreased 9.4% to GBP3.84 billion from GBP4.20 billion. The company's underlying pretax profit increased to GBP52 million from GBP23 million. The company said a reduction in overhead costs to GBP11 million from GBP18 million led to increased profitability. Balfour is proposing an interim dividend increase of 33% to 1.6p per share from 1.2p last year. Looking ahead, the company expects its second half revenue to be in line with the first half. Balfour expects to achieve its underlying profit from operations margin targets in the second half. ----------FTSE 250 - LOSERS----------CLS Holdings, down 2.2%. The property investor reported a rise in interim net asset value as well as solid growth in net rental income for the period. Basic net asset value at the end of the period was 260.2 pence, 3.3% higher than the figure at the end of December, while EPRA net asset value was 3.0% higher at 294.7p. CLS's net rental income rose 8.7% year-on-year to GBP55.0 million, while its vacancy rate fell to 5.7% from 5.8%. Pretax profit for the period was GBP64.9 million, down year-on-year from GBP119.4 million, due to lower property valuation changes as well as the fact the comparable had a significantly higher property sale gain. Looking forward, the company said it is focusing partly on making investments in Germany and the south-east of the UK. The UK as a whole, however, is likely to remain subdued to to Brexit, but Germany and France are benefiting from strong property demand and a limit on new office space.----------OTHER MAIN MARKET AND AIM - WINNERS----------Feedback, up 22%. The medical imaging technology company said its subsidiary has secured its first order for image texture analysis technology TexRAD via GE Healthcare. Feedback said the order follows the distribution agreement, which allows medical technologies & services provider GE Healthcare non-exclusively offer TexRAD for medical imaging research applications. The new order came from the Post Graduate Institute of Medical Education & Research, located in Chandigarh, India. Feedback said its software is currently used in over 50 of the world's leading research institutions across Europe, North America, Asia and Australasia.----------
More News
6 Mar 2023 09:48

LONDON BROKER RATINGS: DB cuts Reckitt; Jefferies likes Tesco

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
1 Mar 2023 09:52

LONDON BROKER RATINGS: Canaccord says sell Future; Investec likes RWS

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
27 Feb 2023 09:38

Berenberg raises target price on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.

Read more
27 Feb 2023 09:26

LONDON BROKER RATINGS: Citi cuts Quilter to 'sell'; Goldman likes GSK

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
24 Feb 2023 09:37

LONDON BROKER RATINGS: SocGen cuts Burberry; BofA cuts WH Smith

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
23 Feb 2023 09:54

Hikma Pharmaceuticals profit halves in 2022 on Generics impairment

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported a dip in annual revenue for 2022, as profit tumbled due to high inflation and adjustments regarding expectations for its Generics business.

Read more
23 Feb 2023 09:02

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.

Read more
23 Feb 2023 07:59

Competition in generics sees Hikma Pharmaceuticals's profits decline by a tenth

(Sharecast News) - Hikma Pharmaceuticals posted lower full-year profits as stiff competition in generics saw its top line growth flatten out.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
22 Feb 2023 21:50

Hikma accuses Amarin of suppressing generic versions of heart pill

Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals

*

Read more
16 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Friday 17 February 
Allianz Technology Trust PLCFull Year Results
Kingspan Group PLCFull Year Results
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
Monday 20 February 
Bank of Cyprus Holdings PLCFull Year Results
Georgia Capital PLCFull Year Results
Goldplat PLCFull Year Results (TBC)
LungLife AI IncFull Year Results
Tristel PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 21 February 
Antofagasta PLCFull Year Results
BHP Group LtdHalf Year Results
Blancco Technology Group PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
HSBC Holdings PLCFull Year Results
InterContinental Hotels Group PLCFull Year Results
Safestore Holdings PLCTrading Statement
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Trifast PLCTrading Statement
Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
25 Jan 2023 09:33

LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
18 Jan 2023 15:07

Director dealings: Hikma Pharmaceuticals director snaps up shares

(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.

Read more
12 Jan 2023 17:55

Arecor transfers AT307 drug to Hikma for development, regains AT282

(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.

Read more
3 Jan 2023 17:31

FTSE 100 ends first trading day of 2023 on upbeat note

FTSE 100 up 1.4%, FTSE 250 adds 1.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.